Healthcare-associated infections among pediatric oncology patients in Pakistan: risk factors and outcome

Naveed-ur-Rehman Siddiqui, Rabia Wali, Anwar-ul Haque, Zehra Fadoo

Department of Pediatric and Child Health, Aga Khan University Hospital, Karachi 74800, Pakistan

Abstract

Introduction: Pediatric oncology patients are at increased risk of contracting healthcare-associated infections (HAIs), which are responsible for increased morbidity and mortality rates as well as treatment costs. This study aimed to identify the frequency of HAIs among pediatric oncology patients and their outcome.

Methodology: Pediatric oncology patients admitted between January 2009 and June 2010 in a pediatric ward at Aga Khan University Hospital, Karachi, Pakistan, who developed HAIs, were analyzed.

Results: A total of 90 HAIs were identified in 32 patients in 70 admissions. The HAI rate among pediatric oncology patients was 3.1/100 admission episodes. Bloodstream infections (63 episodes, 90.0%) were the most common, followed by urinary tract infection (two episodes, 2.9%). Gram-positive infections were seen in 54 (60%) patients, followed by Gram-negative infection in 34 (37.8%), and fungi in 2 (2.8%) cases. Coagulase negative staphylococci was the most common Gram-positive and Escherichia coli and Pseudomonas aeruginosa were most common Gram-negative infections. Mortality rate among pediatric oncology patients who developed HAIs was 12.5% (4/32). Total parental nutrition use and length of stay longer than 30 days were the identified risk factors associated with increased mortality among pediatric oncology patients who developed HAIs.

Conclusion: We report an HAI rate among pediatric oncology patients of 3.1/100 admission episodes with a mortality rate of 12.5% in Pakistan. Further studies should be done, especially in the developing world, to identify the risk factors associated with increased mortality among pediatric oncology patients so that adequate measures can be taken to reduce the mortality among these patients.

Key words: healthcare-associated infections; pediatric oncology patients; bloodstream infection

J Infect Dev Ctries 2012; 5(6):416-421.

(Received 30 October 2010 – Accepted 26 April 2011)

Copyright © 2012 Siddiqui et al. This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited

Introduction

Healthcare-associated infections (HAIs) represent a worldwide health-care problem placing a substantial burden on both individual patients and on health-care systems, which results in major complications of serious illnesses [1]. However, employing new strategies such as the increased use of chemotherapy drugs, white blood cell stimulants, and broad-spectrum antibiotics has improved the outcome of pediatric oncology patients [2]. In spite of such advances, these patients experience long bouts when they are immunocompromised and must remain in hospital for long periods when they will likely require central venous catheterizations, urinary catheterizations, endotracheal intubations, and intravenous feeding tubes [2]. These factors moreover put oncology patients at an increased risk of contracting HAIs and substantially increase morbidity and mortality rates as well as treatment costs [2-4].

The incidence rate of HAI among pediatric oncology patients ranges from 5.2 to 13.3 per 100 hospital admissions and 7.0 to 17.7 per 1000 hospitalization days [2,3,6,7]. Some investigators report bloodstream infections (BSIs), while others report respiratory infections as the most frequent site of HAIs among pediatric oncology patients [2,5,7,8].

Gram-negative bacteria has been isolated most often in some investigations involving pediatric oncology patients, with Pseudomonas aeruginosa being the most common organism detected [5]. However, in other studies, a higher incidence of Gram-positive bacteria has been found with staphylococci being the most commonly detected organism [3,7]. Developing countries like Pakistan represent different health and environmental issues which might affect on rate of HAIs among high risk populations such as pediatric oncology patients. It would be interesting to assess the frequency of HAIs among pediatric oncology patients, infection sites,
and common microorganisms. Therefore, we conducted a retrospective surveillance study to identify the frequency of HAIs among pediatric oncology patients, the most common sites of infection, and organisms responsible for it in a hospital in Pakistan.

**Methodology**

**Setting**

This descriptive, cross-sectional study was conducted in the Department of Pediatrics and Child Health, in the oncology unit, at Aga Khan University Hospital in Karachi, Pakistan, from January 2009 to June 2010. The Aga Khan University Hospital (AKUH) is a 600-bed tertiary-care facility and is accredited by the international arm of the Joint Commission International Accreditation Survey (JCIA). There is a 10-bed, separate oncology ward along with a 5-bed special care unit within the Pediatric Department, run by the pediatric residents and pediatric oncology fellows under the supervision of a pediatric hematologist and oncologist.

**Patient population**

Pediatric oncology patients one month to 18 years of age, who were admitted to the pediatric ward from January 2009 to June 2010, and who developed HAIs according to definitions set by the United States Centers for Disease Control and Prevention (CDC)/National Health Care Safety Network (NHSN) Guidelines [9] were included in the study. All patients received therapy according to ACCM/PALS 2002 [10] Guidelines for pediatric sepsis and multi-organ dysfunction [11].

**Definitions**

HAI, bloodstream infection (BSI), urinary tract infection (UTI), ventilator associated pneumonia (VAP), pneumonia in immunocompromised patients (PNEU3), and gastrointestinal tract infection (GIT) were all defined according to the criteria established by CDC/NHSN Guidelines [9]. Sepsis related diagnosis was made according to the criteria established at the International Pediatric Sepsis Consensus Conference [11].

**Data collection**

All pediatric oncology patients, one month to 18 years of age, who were admitted to the pediatric ward from January 2009 to June 2010, and who developed HAIs according to guidelines set by the Centers for Disease Control and Prevention (CDC)/National Health Care Safety Network (NHSN) [9] were registered in the study. Informed consent was taken from the guardian or parents. The data included demography of the patients’ registration number, age, gender, weight, and height. Data also included primary diagnosis, site of HAIs, and common organism responsible for it. Clinical data, *i.e.* temperature, heart rate, blood pressure, and pertinent laboratory data such as hemoglobin, total leukocyte counts, absolute neutrophil counts, and platelet counts were also included to identify the sepsis related diagnosis according to the guidelines of the International Pediatric Sepsis Consensus Conference [11]. Length of stay, history of blood transfusion, total parental nutrition (TPN), mechanical ventilation (MV), central venous catheters (CVC), and urinary catheter usage were also identified. The final outcome in terms of discharge from the ward or expired was identified.

**Statistical analysis**

The overall frequency of pediatric oncology patients who developed HAIs during the study period was determined by dividing the total number of admissions to pediatric oncology patients with HAIs with the total number of admissions to the pediatric oncology unit. For analysis, SPSS version 16 (IBM, Chicago, USA) was used. Descriptive frequencies were computed for qualitative variables and mean, and ranges were computed for quantitative variables. Pediatric oncology patients who survived after developing HAIs were compared with those who expired after developing HAIs and chi square was used to calculate the P value among these patients.

**Results**

The total number of admissions in the pediatric oncology unit was 2,241. A total of 90 episodes of HAIs were identified in 32 patients in 70 admissions. The HAI rate among pediatric oncology patients was 3.1 HAI /100 admissions. Most of the patients had acute leukemia and lymphomas 62/70 (88.6%), followed by solid tumors (Table 1). The characteristics of patients who developed HAIs are given in Table 2. More than 50% of the patients had hemoglobin counts less than 10gm/dl, white blood count less than 1000/cm, absolute neutrophilic count (ANC) less than 500/cm, and platelet counts less than 50,000/cm. Central venous catheter (CVC) was present in 46 out of 70 (65.7%) patients, in which
38/46 (82.6%) were portal catheter, 7/46 (15.2%) were peripherally inserted central catheter (PICC) line, and 1/46 (2.1%) was femoral line. The most common type of infection was bloodstream infection (BSI) 63/70 (90%), followed by urinary tract infection (UTI). Gram-positive organisms constituted 54/90 (60%) isolates, followed by Gram-negative organisms at 34/90 (37.8%), and fungi at 2/90 (2.2%). Coagulase negative staphylococci were the most common Gram-positive bacteria, and Escherichia Coli and Pseudomonas aeruginosa were the most common Gram-negative organisms details (Table 3). The mortality rate among pediatric oncology patients who developed HAIs was 12.5% (4/32). Total parental nutrition (TPN) use and length of stay longer than 30 days with significant P values were the only identified risk factors associated with increased mortality among patients who developed HAI (Table 4).

**Discussion**

We report a lower frequency of HAIs among pediatric oncology patients compared to the rates of 5.2-13.3/100 hospital admissions observed in previously reported studies [2,3,5,6]. The frequency of HAIs in our cohort was relatively low because we did not include the clinical CDC/NHSN criteria, as our cohort only included the culture-positive results according to CDC/NHSN criteria [9].

In our study, BSI (90%) was the most common HAI, as seen in other cohorts [2,3,7,12]. The most common organism detected in our patients was Gram-positive bacteria, a finding that supports the reported trend of Gram-positive bacterial predominance since the 1980s, [3,13,14], with coagulase-negative staphylococci being the most common bacteria detected, as seen in other cohorts [3,7,15]. The higher rate of Gram-positive bacteria as causal organism for HAIs in European countries could be due to the fact that in European countries central venous catheterization is a commonly performed procedure, as seen in our patients. In our cohort, greater than 70% were severely neutropenic, which might explain the risk factor associated with fungal infections; however, it was difficult to calculate positive correlation due to the small number of fungal infected samples. Therefore, as noted in one study involving oncology patients who had low absolute neutrophil counts for a prolonged period of time, care should be taken to guard against bacterial as well as fungal infections [16].

We report a mortality rate of 12.5%, which is lower than that reported in another investigation which showed a mortality rate of 19.6% [2]. Although we found TPN use and length of stay greater than 30 days to be statistically significant with a high mortality rate among pediatric oncology patients, we were not able to calculate the other risk factors associated with it because of the low mortality rate in our study; however, this observation suggests another area for future research.

In conclusion, we report a low HAI rate among pediatric oncology patients from a hospital in Pakistan. We identified TPN use and length of stay longer than 30 days to be the associated risk factors leading to increased mortality among pediatric oncology patients. However, further studies had to be done to identify the risk factors associated with high mortality rate among pediatric oncology patients, especially in the developing world, so that adequate measures should be taken to reduce the mortality and health care costs.

| Table 1. Diagnosis of admitted pediatric oncology patients who developed HAI |
|------------------------|------------------------|------------------------|
|                        | Number n (%)          |
| **Acute leukemia**     | 51 (72.9)             |
| Acute Lymphoblastic Leukemia | 37 (52.9)       |
| Acute Myeloid Leukemia | 14 (20.0)             |
| **Lymphoma**           | 11 (15.7)             |
| Non Hodgkin Lymphoma   | 10 (14.3)             |
| Hodgkin disease        | 1 (1.4)               |
| **Solid tumors**       | 8 (11.3)              |
| Synovial sarcoma       | 5 (7.1)               |
| Osteogenic sarcoma     | 1 (1.4)               |
| Hepatoblastoma         | 1 (1.4)               |
| Rhabdomyosarcoma       | 1 (1.4)               |

(n = 70)
| Characteristics                      | Number (%) or Mean (Range) |
|--------------------------------------|---------------------------|
| **Age in years**                     |                           |
| 1 month - 5 years                    | 31 (44.3)                 |
| 5 years - 10 years                   | 27 (38.6)                 |
| 10 years - 18 years                  | 12 (17.1)                 |
| Male                                 | 45 (64.5)                 |
| Weight (kg)                          | 20.9 (5-51.5)             |
| Height (cm)                          | 108.8 (74 - 150)          |
| **Site of infection**                |                           |
| BSI                                  | 63 (90)                   |
| UTI                                  | 2 (2.9)                   |
| BSI + PNEU 3                         | 2 (2.9)                   |
| BSI + VAP                            | 2 (2.9)                   |
| GIT                                  | 1 (1.4)                   |
| **Sepsis related diagnosis**         |                           |
| Sepsis                               | 67 (95.8)                 |
| MOD                                  | 3 (4.2)                   |
| **Hemoglobin (gm/dl)**               |                           |
| < 10gm/dl                            | 60 (85.7)                 |
| > 10gm/dl                            | 10 (14.3)                 |
| **WBC /cm**                          |                           |
| < 1000/cm                            | 38 (54.3)                 |
| > 1000/cm                            | 32 (45.7)                 |
| **ANC /cm**                          |                           |
| < 500/cm                             | 51 (72.9)                 |
| > 500/cm                             | 19 (27.1)                 |
| **Platelets /cm**                    |                           |
| < 50,000/cm                          | 38 (54.3)                 |
| > 50,000/cm                          | 32 (45.7)                 |
| **Length of stay (days)**            | 18.2 (4-102)              |
| **TPN given**                        | 17 (24.2)                 |
| **Blood transfusion**                | 60 (85.7)                 |
| CVC                                  | 46 (65.7)                 |
| Porta catheter                       | 38 (82.6)                 |
| PICC line n (%)                      | 7 (15.2)                  |
| Femoral line                         | 1 (2.1)                   |
| **Mechanical ventilation**           | 4 (5.7)                   |
| **Foleys catheter**                  | 4 (5.7)                   |
| **Outcome**                          |                           |
| Discharged                           | 66 (94.3)                 |
| Expired                              | 4 (5.7)                   |

HAI: Hospital acquired infection; BSI: Blood stream infection; UTI: Urinary tract infection; PNU/E3: Pneumonia in immunocompromised; VAP: Ventilator associated pneumonia; GIT: Gastrointestinal tract infection; MOD: Multiorgan dysfunction; WBC: White blood cells; ANC: Absolute neutrophil counts; TPN: Total parenteral nutrition; CVC: Central venous catheter
Table 3. Organisms isolated

| Organism                        | Number (%) |
|---------------------------------|------------|
| **Gram positive organisms**     |            |
| Coagulase negative staphylococci| 37 (40.7)  |
| *Staphylococcus aureus*         | 4 (4.4)    |
| *Streptococcus* species         | 7 (7.8)    |
| *Corynebacterium* species       | 5 (5.6)    |
| *Bacillus* species              | 4 (4.4)    |
| **Gram negative organisms**     | 34 (37.8)  |
| *Escherichia coli*              | 7 (7.8)    |
| *Pseudomonas aeruginosa*        | 7 (7.8)    |
| *Klebsiella pneumoniae*         | 6 (6.7)    |
| *Acinetobacter* species         | 4 (4.4)    |
| *Enterobacter* species          | 4 (4.4)    |
| *Pseudomonas cepacia*           | 1 (1.1)    |
| *Pseudomonas stutzeri*          | 1 (1.1)    |
| *Stenotrophomonas maltophilia*  | 1 (1.1)    |
| **Fungi**                       | 2 (2.2)    |
| *Candida tropicalis*            | 1 (1.1)    |
| *Aspergillus flavus*            | 1 (1.1)    |

(n = 90)

Table 4. Characteristics of admitted pediatric oncology patients with HAI who discharged and expired

|                          | Discharged (n = 66) | Expired (n = 4) | P value |
|--------------------------|---------------------|-----------------|---------|
|                          | Number (%)          | Number (%)      |         |
| Male                     | 41 (62.1)           | 4 (100)         | 0.289   |
| 5 years - 10 years       | 24 (36.4)           | 3 (75)          | 0.165   |
| Hemoglobin < 10gm/dl     | 56 (84.8)           | 4 (100)         | 0.251   |
| WBC < 1000/cm            | 34 (51.5)           | 4 (100)         | 0.222   |
| ANC < 500/cm             | 47 (71.2)           | 4 (100)         | 0.637   |
| Platelets < 50,000/cm    | 34 (51.5)           | 4 (100)         | 0.166   |
| Length of stay (> 30 days)| 7 (10.6)           | 4 (100)         | 0.001   |
| TPN given                | 13 (19.7)           | 4 (100)         | 0.035   |
| Blood transfusion        | 56 (84.8)           | 4 (100)         | 0.532   |
| CVC                      | 42 (63.6)           | 4 (100)         | 0.627   |

HAI: Hospital acquired infection; WBC: White blood cells; ANC: Absolute neutrophil counts; TPN: Total parental nutrition; CVC: Central venous catheter
Acknowledgments
We are thankful to Department of Pediatric and Child Health, Aga Khan University Hospital for its support and helping us throughout the study. No funding agency was involved for the study.

References
1. Graves N (2004) Economics and preventing hospital-acquired infection. Emerg Infect Dis 10: 561-566.
2. Oberdorfer P, Pongwilairat N, Washington CH (2009) Nosocomial Infections among Pediatric Patients with Neoplastic Diseases. Int J Pediatr 2009: 721320.
3. Urrea M, Rives S, Cruz O, Navarro A, Garcia JJ, Estella J (2004) Nosocomial infections among pediatric hematology/oncology patients: results of a prospective incidence study. Am J Infect Control 32: 205-208.
4. Chen YY, Chou YC, Chou P (2005) Impact of nosocomial infection on cost of illness and length of stay in intensive care units. Infect Control Hosp Epidemiol 26: 281-287.
5. Wang A, Fan S, Yang Y, Shen X (2008) Nosocomial infections among pediatric hematology patients: results of a retrospective incidence study at a pediatric hospital in China. J Pediatr Hematol Oncol 30: 674-678.
6. Simon A, Fleischhacker G, Hasan C, Bode U, Engelhart S, Kramer MH (2000) Surveillance for nosocomial and central line-related infections among pediatric hematology-oncology patients. Infect Control Hosp Epidemiol 21: 592-596.
7. Al-Tonbary YA, Soliman OE, Sarhan MM, Hegazi MA, El-Ashry RA, El-Sharkawy AA, Salama OS, Yahya R. Nosocomial infections and fever of unknown origin in pediatric hematology/oncology unit: a retrospective annual study. World J Pediatr 7: 60-64.
8. Urrea M, Pons M, Serra M, Latorre C, Palomeque A (2003) Prospective incidence study of nosocomial infections in a pediatric intensive care unit. Pediatr Infect Dis J 22: 490-494.
9. Horan TC, Andrus M, Dudeck MA (2008) CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control 36: 309-332.
10. Cercillo JA and Fields AI (2002) Clinical practice parameters for hemodynamic support of pediatric and neonatal patients in septic shock. Crit Care Med 30: 1365-1378.
11. Goldstein B, Giroir B, Randolph A (2005) International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 6: 2-8.
12. Raymond J and Aujard Y (2000) Nosocomial infections in pediatric patients: a European, multicenter prospective study. European Study Group. Infect Control Hosp Epidemiol 21: 260-263.
13. Simon A, Ammann RA, Bode U, Fleischhacker G, Wenchel HM, Schwamborn D, Gravou C, Schlegel PG, Rutkowski S, Dannenberg C, Köhrholz D, Laws HJ, Kramer MH (2008) Healthcare-associated infections in pediatric cancer patients: results of a prospective surveillance study from university hospitals in Germany and Switzerland. BMC Infect Dis 8: 70.
14. Laws HJ, Schneider DT, Janssen G, Wesselowski R, Diloo D, Meisel R, Adams O, Mackenzie C, Göbel U (2007) Trends in infections in children with malignant disease in 2000: comparison of data of 1980/81. Pediatr Hematol Oncol 24: 343-354.
15. Ford-Jones EL, Mindorff CM, Langley JM, Allen U, Navas L, Patrick ML, Milner R, Gold R (1989) Epidemiologic study of 4684 hospital-acquired infections in pediatric patients. Pediatr Infect Dis J 8: 668-675.
16. Cullen M, Steven N, Billingham L, Gaunt C, Hastings M, Simmonds P, Stuart N, Rea D, Bower M, Fernando I, Huddart R, Gollins S, Stanley A (2005) Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med. 353: 988-998.

Corresponding author
Dr. Naveed-ur-Rehman Siddiqui
Resident Pediatric and Child Health
Aga Khan University Hospital
Stadium Road, PO BOX 3500
Karachi 74800, Pakistan
Telephone: 4930051 ext: 4387, Mobile no: 0213-322273037
Email: naveed.rehman@aku.edu,

Conflict of interests: No conflict of interests is declared.